Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 746 | 4,310 | 1,673 | 2,212 | 3,053 |
| Receivables | N/A | 420 | 4 | 1,205 | 22 |
| TOTAL | $2,009 | $7,245 | $2,928 | $5,282 | $4,401 |
| Non-Current Assets | |||||
| PPE Net | 118 | 124 | 124 | N/A | N/A |
| Other Non-Current Assets | 42 | 83 | 128 | 293 | 211 |
| TOTAL | $159 | $208 | $251 | $293 | $211 |
| Total Assets | $2,168 | $7,453 | $3,180 | $5,575 | $4,612 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,610 | 3,268 | 464 | 1,043 | 615 |
| Accrued Expenses | 981 | 993 | 1,454 | 1,046 | 889 |
| TOTAL | $2,837 | $4,568 | $2,305 | $2,513 | $1,761 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 1 | 0 | 1 | 130 |
| TOTAL | $N/A | $N/A | $0 | $1 | $130 |
| Total Liabilities | $2,837 | $4,568 | $2,305 | $2,514 | $1,891 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 14,694 | 9,278 | 3,541 | 2,968 | 2,371 |
| Common Shares | 1 | 1 | 0 | 0 | 0 |
| Retained earnings | -143,276 | -139,720 | -136,952 | -133,223 | -131,490 |
| Other shareholders' equity | -329 | -329 | -329 | -329 | -329 |
| TOTAL | $-669 | $2,885 | $875 | $3,060 | $2,721 |
| Total Liabilities And Equity | $2,168 | $7,453 | $3,180 | $5,574 | $4,612 |